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Abstract  
 
Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central 
nervous system lymphomas that are based in the posterior eye. These tumours are 
challenging to treat, and today management generally involves a multispecialty team 
coordinating a treatment protocol that may include intraocular chemotherapy, ocular 
irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The 
ophthalmologist has specific responsibility for the intraocular chemotherapy, which is 
delivered to the eye by intravitreal injection. The most commonly injected drugs are 
methotrexate – an anti-metabolite – and rituximab – an anti-human B cell monoclonal 
antibody. A range of intraocular chemotherapy treatment schedules have been 
described in the medical literature, although to date there have been no randomised 
clinical trials of these schedules. In this article, we review the development and current 
status of intraocular chemotherapy for vitreoretinal lymphoma. 
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Introduction 
 
Vitreoretinal lymphoma (VRL) is a subgroup of primary central nervous system 
lymphoma (PCNSL) that is based in the posterior segment of the eye.1,2 Most cases of 
this tumour represent an aggressive form of diffuse large B cell lymphoma, but T cell 
intraocular lymphoma also has been described.3 Vitreoretinal lymphoma is rare: a 
relatively recent estimate calculated from North American data indicates an incidence 
of 0.048 cases per 100 000 people each year.4 When PCNSL first presents in the eye, 
VRL is termed ‘primary’. However, for a majority of patients, if not at presentation, VRL 
ultimately also involves the intracranial CNS, which is associated with considerable 
morbidity and high mortality.5  
 
The majority of persons who present with VRL are over 50 years of age, and there is 
no clear sex predilection.1,2 Typically, the patient is first diagnosed with intermediate 
and/or posterior uveitis, manifest as vitritis and/or subretinal infiltrates.1,2 Less 
commonly there is optic nerve or anterior segment infiltration. The patient is often 
troubled by floaters, but has visual acuities that are unexpectedly good. A diagnosis of 
VRL is made when cytology and flow cytometry of ocular samples identify a 
monoclonal neoplastic B lymphocyte population; ancillary testing may detect elevated 
interleukin-10 in intraocular fluid and/or demonstrate of clonal immunoglobulin heavy-
chain gene rearrangements or mutation in the myeloid differentiation primary response 
gene 88 (MYD88) in tumour cells.6 Several ocular biopsy procedures may be required 
to make this diagnosis, since in many cases, tumour cells are fragile and sparse.7 
Corticosteroid drugs are lymphotoxic, and it is recommended that sampling be 
postponed for a few weeks if the patient has been taking local and/or systemic 
corticosteroids, in order to maximise the yield of malignant cells.8 
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There is a limited evidence-base to guide the management of VRL. There have been 
no randomised clinical trials directed at the management of VRL specifically, although 
some clinical trials of treatments for PCNSL have included patients with VRL, allowing 
limited subset analyses.9 Therapeutic choices therefore depend in part on the expertise 
of a multispecialty medical team that may involve ophthalmologists, neurologists, 
oncologists and/or radiotherapists. Treatment regimens include one or more of the 
following options: intraocular chemotherapy, ocular irradiation that may be combined 
with whole brain radiotherapy, a number of systemic chemotherapy protocols (which 
may be directed to the CNS with hyper-osmotic blood-brain barrier disruption), and 
following chemotherapy, autologous stem cell transplantation; intrathecal 
chemotherapy is not widely used today after recent clinical trials showed no benefit 
over systemically delivered drugs in patients with PCNSL.10 The ophthalmologist is 
expert in the use of intraocular chemotherapy in particular. In this article, we review 
developments in and the current status of intraocular chemotherapy for VRL.  
 
Overview of intraocular chemotherapy for vitreoretinal lymphoma  
 
Intraocular chemotherapy for VRL involves the delivery of drugs to the posterior eye by 
intravitreal injection. There are several possible indications for this intervention, and it 
may be given as the primary therapy, or as adjunctive therapy to more extensive 
treatments. Resolution of the tumour improves bothersome floaters and blurred vision, 
and limits the potential for retinal or retinal pigment epithelial damage, related to 
infiltration with tumour sheets.1 Local delivery also avoids the potentially serious 
systemic toxicity of the chemotherapeutic agent. However, treatment may be given for 
the express goal of improving overall survival from PCNSL.11 Macular oedema is an 
unusual presenting sign of primary VRL, and occurs more often as a complication of 
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medical or surgical interventions.12 Thus, macular oedema in particular may not be an 
indication for intraocular chemotherapy. 
 
A range of drugs have been used in intraocular chemotherapy. The majority of 
published literature in this field focuses on the use of methotrexate. Intraocular 
methotrexate – an anti-metabolite – was first administered to a patient with VRL 
approximately 25 years ago, as reported by De Smet et al of the National Eye Institute 
of the National Institutes of Health (NEI/NIH, Bethesda, MD)13 at the American 
Academy of Ophthalmology annual meeting. The group had observed that 
methotrexate achieved tumouricidal concentrations within the eye for 3 days when 
administered at high dose intravenously.14 They subsequently described the 
pharmacokinetics of a single intraocular injection of methotrexate in the blind eye of a 
patient with recurrent VRL: an intravitreal injection of 400 µg injected intravitreally 
resulted in concentrations that were lymphocytotoxic for 5 days.15 Importantly, this 
treatment was administered without ocular complications. Although originally 
developed at the NEI/NIH, intraocular chemotherapy with methotrexate is now used 
widely internationally.2,11 
 
While usually highly effective in inducing remission, the need for frequent injections of 
this drug and reports of tumour recurrence after the course of methotrexate treatment 
led to an interest in other chemotherapeutic agents. Just over one decade ago, the first 
reports of treating VRL with the anti-B cell chimaeric mouse/human monoclonal 
antibody – rituximab – were published. The observation that intrathecal rituximab 
resulted in a reduction in tumour load in VRL was soon followed by use of the drug 
intravitreally in patients with VRL.16 Initial studies in rabbits showed pan-retinal 
penetration and an absence of retinal and optic nerve pathology following intravitreal 
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administration of rituximab, and provided pharmacokinetic evidence that the drug would 
achieve detectable levels within the eye for several months after an injection.17-19 
Kitzmann et al from the Mayo Clinic (Rochester, MN)18 described the first experience in 
humans after treating 5 eyes of three patients without complications. Since the first 
descriptions, a number of groups have combined rituximab with methotrexate in their 
treatment protocols, which also is consistent with the treatment of other forms of diffuse 
large B cell lymphoma.20  
 
Additional drugs have also been used in intraocular chemotherapy protocols for VRL, 
albeit less often, including thiotepa,15 melphalan21 and corticosteroid.22 Here we 
describe the technique of intravitreal injection, ahead of summarising clinical studies of 
the different chemotherapeutic drugs delivered into the eye (Table 1), and considering 
the role of intraocular chemotherapy in the management of PVRL.  
 
Technique of intravitreal injection 
 
Intravitreal injection is widely used for delivery of multiple classes of drugs to the eye, 
and has been shown to be safe and well tolerated in large patient cohorts. Ocular 
irritation, conjunctival hyperaemia and limited subconjunctival haemorrhage are 
common following the procedure, but usually resolve promptly. The most serious 
complication is endophthalmitis, which has an estimated rate of 0.05% in a meta-
analysis of 105,536 cases injections of antibody against vascular endothelial growth 
factor.23 Intraocular haemorrhage and retinal detachment are other visually significant 
complications, which are reported at rates of 0.06% (in a series of 7113 injections)24 
and 0.01% (in a series of 35,942 injections),25 respectively. Raised intraocular pressure 
is also possible, but is readily monitored and addressed by anterior chamber 
paracentesis if necessary.26 
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Table 1. Summary of clinical studies of intravitreal chemotherapy for vitreoretinal 
lymphoma, identified by first author last name and reference number. Individual case 
reports have not been included.  
 
Drug* 
 
 
Report (number of eyes/patients) 
 
Methotrexate 
 
 
Fishburne et al29 (7/4); Smith et al30 (26/16); Frenkel et 
al34 (44/26); Sou et al35 (10/6); Akiyama et al36 (17/10); 
Ma et al37 (29/19); Kaburaki et al38 (27/17); Klimova et 
al39 (34/20); Cho et al40 (NS/16); Smith et al50 (122/74) 
 
 
Rituximab 
 
 
Kitzmann et al18 (5/3); Ohguro et al55 (3/2); Hashida et 
al56 (20/13); Cicinelli et al59 (18/9) 
 
 
Ritixumab ± Methotrexate 
 
 
Larkin et al20 (48/34) 
 
Melphalan 
 
 
Shields et al21 (3/2) 
 
Drug not specified and/or 
outcome not reported 
separately from outcomes 
of other treatments 
 
 
Levasseur et al4 (NS/NS) ; Castellino et al22 (NS/24); 
Turaka et al46 (6/3); Abu Samra et al47 (NS/26); Dalvin 
et al48 (NS/NS); Grimm et al66 (NS/11); Grimm et al67 
(NS/23); Riemens et al68 (NS/21)  
Abbreviation: NS = not specified 
*In addition to the treatments listed, intravitreal chemotherapy with thiotepa has been 
reported in 1 patient,15 and in one study listed under “drug not specified and/or 
outcome not reported separately from outcomes of other treatments”, corticosteroid 
was included in the intravitreal chemotherapy.22  
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For the benefit of readers who are not ophthalmic surgeons, we describe a typical 
injection procedure (used by co-author, SRL), recognising that there are multiple minor 
variations on this technique. Two eyedrops of 0.5% amethocaine hydrochloride are 
administered to the eye, spaced 1 minute apart. After 2 minutes, the site is prepared 
with 5% povidone-iodine solution, and a speculum is used to separate the eyelids and 
clear the field of eyelashes. A volume of 0.2 mL of 2% lignocaine is injected 
subconjunctivally in the superotemporal region of the eye with a 30 G needle to 
produce a small conjunctival bleb. The intravitreal injection is given with a new 30 G 
needle through the anaesthetised area, 3.5 or 4 mm behind the limbus in patients with 
an intraocular lens or their natural lens, respectively, and directed towards the centre of 
the vitreous cavity. Following the injection, the speculum is removed, and the eye is 
irrigated with 0.9% normal saline to minimise late ocular irritation. No eye pad, 
antibiotics, sedatives or pain relief are given.  
 
Intraocular methotrexate therapy 
 
Methotrexate is an anti-metabolite that acts by competitive inhibition of the enzyme, 
dihydrofolate reductase, ultimately resulting in reduced synthesis of thymine, which is 
an essential nucleobase in DNA.27 This drug became a cornerstone of the treatment of 
non-Hodgkin lymphoma in the 1970s.28 Twenty years later, in the mid-1990s, the first 
small cohort of patients was treated with intraocular methotrexate for VRL: at Oregon 
Health & Science University (OHSU, Portland, OR), Fishburne et al29 managed 7 eyes 
of 4 patients – tested negative for the human immune-deficiency virus (HIV) – with a 
14-month course of intravitreal methotrexate injections, in conjunction with systemic 
chemotherapy delivered by hyper-osmotic blood-brain barrier disruption. All eyes 
demonstrated remission of the tumour after a median of 6 injections and a maximum of 
9 
 
11 injections per eye. The authors reported “no serious ocular toxic reaction” in any 
eye, and stable visual acuity in 6 of 7 eyes after a median of 14 months follow-up.  
 
In 2002, the OHSU group teamed up with ocular oncologists at Hadassah University 
(Jerusalem, Israel) to publish a report detailing outcomes in a larger group of 16 HIV-
negative patients with VRL treated by intraocular methotrexate, with slight 
modifications on the injection schedule: Smith et al30 reported the use of intravitreally 
injected methotrexate in 3 phases: induction (ie. twice weekly for 1 month), 
consolidation (ie. weekly for 1-2 months) and maintenance (ie. monthly for 9-12 
months). Remission was achieved in all 26 eyes of 16 patients after a median of 8.5 
injections and maximum of 12 injections per eye. In general, the intraocular 
chemotherapy was combined with systemic chemotherapy, which involved quite 
diverse protocols. However, two patients with isolated bilateral primary VRL were given 
local chemotherapy as sole treatment. Six of 16 patients died in follow-up, as a result of 
progressive intracranial tumour, but without clinical ocular involvement on the final eye 
examination. Notably, for 3 patients whose VRL recurred in follow-up (median of 18 
months), the tumour was again put into remission with a second course of intravitreal 
methotrexate injections. 
 
The report by Smith et al30 also provided a detailed description of the potential adverse 
events associated with intraocular methotrexate therapy, noting the possibility that 
some of these might be related to the vitrectomy required to make the diagnosis, the 
systemic therapy that was co-administered and/or the tumour itself. In particular, hyper-
osmotic blood-brain barrier disruption is associated with a maculopathy,31,32 and VRL 
may produce retinal pigment epithelial detachments that result in atrophy, pigmentary 
changes and disciform scars.33 Complications that occurred in injected eyes during the 
treatment period were: progression of cataract (73%), corneal epitheliopathy (58%), 
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maculopathy (42%), vitreous haemorrhage (8%), optic atrophy (4%) and sterile 
endophthalmitis (4%). Corneal epitheliopathy is avoided by taking care to avoid spillage 
of drug onto the ocular surface during the procedure, with washing if necessary, and 
treated with the use of folinic acid 0.003% eye drops 4 times daily.30 No patient 
suffered loss of vision that could be definitely attributed to the treatment.  
 
Subsequent to the original clinical case series, medical centres in North America, 
Europe, the Middle East and Asia also have reported their experience in treating 
groups totalling at least 177 eyes of 114 patients with VRL,34-40 as well as multiple 
individual patients,41-45 using intravitreal methotrexate injections. Additional reports 
have described groups of patients suffering from VRL, who received a range of 
treatments that included methotrexate and/or rituximab intravitreal injections (see 
below).4,22,46-48 Outcomes reported for the 114 patients were consistent with those 
previously reported by the OHSU and Hadassah University investigators.30 In 
summary, the treatment appeared to be highly effective at inducing ocular remission of 
the VRL, and was also used successfully to re-induce remission in cases of recurrent 
tumour. As in the original reports, many patients received concurrent systemic 
treatments for PCNSL, making it difficult to dissect the therapeutic benefit of intravitreal 
methotrexate specifically, but those patients treated with the local therapy alone also 
experienced disease remission. The majority of patients whose data were reported in 
these studies did not experience loss of vision. Corneal epitheliopathy was identified as 
the most common complication, and in addition to the other side effects originally 
described, glaucoma also was observed to complicate treatment. Although infrequent, 
cases of neovascular glaucoma have been described.49 
 
Today, the largest experience with intravitreal methotrexate therapy for VRL has 
occurred at Hadassah University. At the 2018 Association for Research in Vision and 
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Ophthalmology and Champalimaud Foundation Oncogenesis and Oncology 
Conference, Professor Jacob Pe’er lectured about the team’s experience dating back 
more than 20 years, as summarised in the meeting proceedings.50 In total, the group 
has treated 122 eyes of 74 patients with VRL, and have observed remission of the 
tumour in all cases after a range of 2 to 16 intravitreal methotrexate injections. A small 
number of recurrent cases have been successfully re-treated, and side effects are 
described as “mostly superficial and temporary”.  
 
Intraocular methotrexate therapy also has been used to treat those cases of VRL which 
occur as T cell lymphomas. In 2016, a multinational group based across the United 
States and Europe reported the clinical data from 7 patients with this very rare cancer, 
of whom three women and one man were treated with intravitreal injections of 
methotrexate, along with systemic chemotherapy and in one case, local radiotherapy.51 
For three patients, tumour remission was achieved, although this recurred immediately 
on cessation of the intraocular chemotherapy in one individual. The fourth patient 
developed treatment-limiting keratopathy while the tumour was still clinically present.  
 
There are some differences in practice between institutions when using intravitreal 
methotrexate monotherapy to treat VRL. The vast majority of treating ophthalmologists 
inject methotrexate at a dose of 400 μg (in 0.1 mL). However, the number of injections 
varies quite widely. There are generally three phases of treatment – an intensive 
frequency induction phase; a reduced frequency consolidation phase; and a low 
frequency maintenance phase – and the total course is completed over approximately 
one year. While the Hadassah University protocol involves 25 injections, other reported 
protocols have involved considerably less. For example, Karimi et al44 published the 
description of a young adult man, whose isolated, bilateral VRL was put into extended 
remission with three right eye injections and two left eye injections of intravitreal 
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methotrexate over a 6-month period following pars plana vitrectomy. Klimova et al,39 
who reported on the treatment for 34 eyes of 20 patients with VRL, also preferred a 
less intensive injection schedule, treating “according to the clinical behaviour of the 
lymphoma”.  
 
Resistance during intraocular methotrexate therapy is unusual, but has been reported. 
Sen et al42 used intravitreal injections of methotrexate to treat a 57-year-old woman 
with isolated, unilateral VRL. This treatment initially was highly effective, inducing 
tumour remission, but subsequently the disease became resistant to the cytotoxic 
effect of the drug. In comparison to malignant lymphocytes taken from the eye of a 
patient whose tumour responded well to intravitreal methotrexate, intraocular 
lymphocytes from this patient exhibited decreased expression of drug influx proteins, 
and increased expression of drug efflux proteins. The finding suggested to the authors 
that their patient’s tumour had acquired the ability to reduce intracellular accumulation 
and metabolism of the methotrexate. Ocular radiotherapy was substituted for the 
intraocular chemotherapy, and fortunately effected a lasting remission of the VRL. 
 
Intraocular rituximab therapy 
 
Rituximab is a chimaeric mouse-human monoclonal antibody specifically targeted to 
human cluster of differentiation 20 (CD20). CD20 is a protein that participates in the 
generation of T lymphocyte-independent antibody responses; it is present on the 
surface of B lymphocytes from pre-B cell through mature B cell, and lost when the cells 
terminally differentiate into plasma cells.52 Thus, CD20 is also present on 
lymphomatous cells in most cases of PCNSL and VRL. In targeting B lymphocytes, 
rituximab effects depletion of the B lymphocytes by multiple mechanisms that include 
antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and 
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lymphocyte apoptosis. The drug is used systemically in the treatment of a range of B 
lymphocyte-mediated diseases: autoimmune diseases, including some forms of 
uveitis;53 and B cell lymphomas, including PCNSL.54 The first reported uses of 
intraocular rituximab therapy for VRL were in 2007, by Kitzmann et al from Mayo Clinic 
(Rochester, MN)18 and Ohgura et al from Osaka University Medical School (Osaka, 
Japan):55 a total of 8 eyes of 5 patients were treated with up to 4 intravitreal injections 
of rituximab. The follow-up intervals were short, but all injected eyes showed partial or 
complete remission of VRL following the treatment, which also was well tolerated. 
Treatment with intraocular rituximab therapy in larger groups of patients with VRL 
followed for longer intervals were published a few years after the initial reports. 
Hashida et al56 provided an update on the experience at Osaka University Medical 
School by describing the treatment of 20 eyes of 13 patients who were followed for at 
least one year. The indication for rituximab in all patients was methotrexate treatment-
limiting corneal epitheliopathy. Intravitreal injections of rituximab were given weekly for 
4 weeks, resulting in remission of VRL in all eyes; tumours recurred in 55% of eyes, 
and these recurrences were managed with additional courses of treatment. Case 
reports and small series have detailed consistent experiences with intraocular rituximab 
therapy at ophthalmology centres in other countries, including Puerto Rico, Spain and 
Italy.57-59 In addition, a number of North American eye clinics have published outcomes 
of VRL patient cohorts cumulatively totalling almost 200 individuals, including some 
patients treated with intravitreal rituximab and/or methotrexate therapy; while these 
studies indicate treatment remissions, the impact of the local therapy specifically is not 
readily dissected since multiple approaches to treatment are included.4,22,46-48 
 
In 2014, Larkin et al20 presented what is still the largest published experience with 
intraocular rituximab therapy to date, including 48 eyes of 34 patients, managed at 
clinics across 5 countries (ie. United States, Canada, Brazil, Germany and Australia). 
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The most common dosing interval in these eyes was monthly, and a median of 4 
injections were administered per eye. Approximately two-thirds of eyes were also 
injected intravitreally with methotrexate, usually on the same day as the rituximab, and 
approximately two-thirds of patients were treated with more extensive cytotoxic 
therapies. Overall, complete and partial remissions were observed in 65% and 23% of 
treated eyes, respectively. For those eyes treated with intraocular chemotherapy alone, 
53% of eyes experienced complete remission and 11% experienced partial remission. 
After a median follow-up of 18 months, VRL in 23% of eyes with initial complete 
remission had recurred.  
 
The multi-national study reported by Larkin et al20 also detailed ocular adverse events 
experienced during the period of intraocular chemotherapy with rituximab. 
Complications were reported as (1) related to intraocular rituximab therapy (or unable 
to exclude the treatment as a cause), and (2) not related to intraocular rituximab 
therapy. Amongst the 48 treated eyes, complications included: cataract (19%), 
elevated intraocular pressure (4%), granulomatous anterior uveitis (2%), vitreous 
haemorrhage (2%) and rhegmatogenous retinal detachment (2%). A two-or-greater line 
loss in Snellen visual acuity was associated with the treatment in 4% of eyes. 
Granulomatous anterior uveitis with raised intraocular pressure also was reported by 
Hashida et al,56 but was considerably more common, affecting 35% of the 20 treated 
eyes. Retinal occlusive vasculopathy is a newly identified potential complication, 
reported in a 2019 case report of an 89-year-old man whose VRL was treated with 
ocular chemotherapy.60 
 
The intravitreally injected dose of rituximab used by the multiple clinicians who have 
reported on this treatment of VRL to date is consistently 1 mg (in 0.1 mL). However, 
there are marked differences in the frequency of the injections. In the study reported by 
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Larkin et al,20 ophthalmologists administered at a frequency that varied from single or 
“as indicated” injections to 2-monthly injections. While rituximab is administered 
intravitreally in the vast majority studies, one report from the Massachusetts Eye 
Research and Surgery Institution described intracameral injection of the drug.47 
Hashida et al56 have reported on a waning in effectiveness of intravitreal rituximab 
injections: resistance is well described in the field of systemic lymphoma treatment, 
with various mechanisms proposed, including altered CD20 expression or signalling, 
increase in the apoptotic threshold of the lymphomatous cells, modulation of 
complement activity and/or reduced cellular cytotoxicity.61 
 
Other intraocular chemotherapy 
 
Thiotepa  
As reported by De Smet et al,13,15 the first patient with VRL treated with intraocular 
chemotherapy had intravitreal injections of thiotepa (2 mg in 0.1 mL), in addition to 
methotrexate. Thiotepa is an organophosphorus alkylating agent, which results in 
crosslinking of the double-stranded DNA helix and interferes with DNA replication.62 
This drug was added because, at that time, thiotepa was the only drug that had been 
used intravitreally – for treatment of retinoblastoma63 – and De Smet et al could not be 
certain methotrexate alone would be sufficiently cytotoxic for VRL. However, the 
injections of thiotepa were associated with acute, high rises in intraocular pressure 
resulting in loss of visual acuity, despite aspiration of vitreous fluid prior to the injection 
procedure. Given this complication, and the concurrent work from Fishburne et al29 
showing methotrexate alone was sufficient to induce VRL remission, intraocular 
thiotepa therapy did not become part of standard practice.  
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Melphalan 
In 2017, Shields et al21 published a brief report of intraocular melphalan therapy for 
VRL, following their treatment of three eyes of two patients with intravitreal injections 
(10 μg in 0.1 mL). Melphalan is a phenylalanine derivative of nitrogen mustard and an 
alkylating agent.64 One patient – a 92-year-old woman with bilateral primary VRL – 
experienced clinical remission of the tumour within 3 weeks of single intravitreal 
injections. Subsequent tumour recurrences in one eye were controlled with 6 bimonthly 
injections, and there were no recurrences in the other eye during 19-month follow-up. 
The second patient – a 65-year-old male with bilateral VRL – was treated with 
intravitreal melphalan in one eye and intravitreal methotrexate in the other eye. One 
injection of melphalan was sufficient, while 19 injections of methotrexate were required, 
for control of the tumour. The group observed no retinal toxicity in these patients, and 
have continued to develop this form of ocular chemotherapy, with a total of 12 patients 
reported in their recent description of all patients with VRL treated at the Wills Eye 
Hospital Ocular Oncology Service over a period of 35 years.48 The therapy has been 
adopted by at least one other centre: in 2019, Damato et al65 presented an audit of 10 
patients with VRL treated at University of California, San Francisco, one of whom was 
successfully treated with intravitreal melphalan injections. 
 
Corticosteroids 
In discussing their use of combination methotrexate and thiotepa intraocular 
chemotherapy for VRL, De Smet et al15 suggested the use of corticosteroid as an 
alternate second agent for the treatment of VRL: “(S)ingle agent treatment in the 
setting of recurrent tumour is not usually recommended. Another potential choice is 
direct intraocular treatment with dexamethasone or a long acting steroid preparation”. 
Corticosteroids have lymphocytotoxic effects, which is why VRL masquerading as 
uveitis may show partial response to treatment with different corticosteroid preparations 
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that are prescribed before the diagnosis of lymphoma is recognised.1 While most 
ophthalmologists combine methotrexate and rituximab as multi-agent chemotherapy for 
VRL, some groups include intravitreal corticosteroid in their management of VRL.22  
 
Role of intraocular chemotherapy for vitreoretinal lymphoma 
 
The place of intraocular chemotherapy, and eye-directed therapies in general, in the 
management of VRL continues to be intensely debated, particularly in the setting of a 
primary tumour without other CNS involvement. The International PCNSL Collaborative 
Group used retrospectively collected data in two studies, published in 2007 and 2008, 
to address the role of ocular or local therapy –  including intraocular chemotherapy with 
methotrexate or ocular irradiation – in VRL.66,67 In their study of 83 HIV-negative 
patients with primary VRL, progression-free and overall survival were comparable for 
patients treated with local therapy alone versus patients treated with more extensive 
therapy (with or without local therapy).64 The investigators concluded that local therapy 
alone might be used in this setting, for reduced treatment toxicity without negative 
impact on prognosis. In their study of 221 HIV-negative patients with PCNSL and VRL, 
the risk of relapse in the eye was not reduced by adding local therapy to the treatment 
schedule: progression-free survival was significantly extended, but overall survival was 
similar for patients treated with or without local therapy, in addition to more extensive 
treatments.67 The investigators surmised that local treatment was appropriate for 
patients with PCNSL and VRL, to give prolonged remission of the ocular disease. On 
the basis of these studies primarily, 2015 European Association for Neuro-Oncology 
Guidelines state that VRL in PCNSL should be treated as PNCSL, and that primary 
VRL may be managed with systemic therapy or local treatment, including intraocular 
chemotherapy.    
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Studies conducted since the 2015 European Association for Neuro-Oncology 
Guidelines were written have provided different perspectives on the effectiveness of 
eye-directed therapies – most often intraocular methotrexate therapy – in prolonging 
the onset or progression of CNS disease in patients with VRL. In 2015, Riemens et al68 
reported data that were collected across 17 European centres, comparing 75 patients 
who were treated with local, extensive and combined local and extensive therapies for 
primary VRL: rates for development of CNS involvement and death were the same 
across treatment groups. In contrast, as reported in 2019, for 66 patients with VRL 
treated at Mayo Clinic with systemic and ocular therapy (primarily intravitreal 
methotrexate, rituximab and/or corticosteroid therapy) had significantly longer failure-
free and CNS relapse-free survival, but no increase in overall survival than patients 
treated with local or systemic treatment alone.22 A smaller 2018 report from Charles 
University and General Hospital University (Prague, Czech Republic)39 provided 
additional data in support of a combined extensive and local treatment approach to 
VRL: in 10 patients with primary VRL, combined therapy with intravitreal methotrexate 
extended progression-free survival, but not overall survival. Two non-comparative 
studies from Japan involving 27 patients with VRL provide further support for 
combination treatment, including intravitreal methotrexate as ocular therapy, for 
primary VRL.36,38 While the best approach to managing VRL continues to be discussed, 
choice of treatment also will depend on general physical health and medical history, as 
noted in the 2015 European Association for Neuro-Oncology Guidelines.69 
 
Conclusion  
 
Intraocular chemotherapy was originally described as a treatment option for VRL over 
20 years ago. Clearly the treatment – presently in the form of methotrexate, rituximab 
and melphalan – is effective in inducing intraocular tumour remissions, with an 
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acceptable side effect profile. Patients benefit symptomatically from the resolution of 
vitreous and/or retinal infiltration. Additionally, locally delivered therapy spares the 
patient potentially serious complications of more extensive anti-lymphoma therapies. 
This is a particularly important consideration since the majority of patients with VRL are 
older adults. Over the coming 5 to 10 years, therapeutic advances may be expected in 
two main areas: drugs and modes of delivery. As reviewed recently by Touhami et al,70 
a number of new biologic agents – such as the programmed cell death protein-1 
blocker, nivolumab, and bruton tyrosine kinase inhibitor, ibrutinib – show promise for 
management of PCNSL, and might become candidates for intraocular injection. In 
parallel, experimental studies in the rabbit seek to reduce the number of injections with 
a biodegradable intraocular drug delivery device,71 or to avoid intraocular injections 
entirely by iontophoresis.72 Ultimately, the goal in treating VRL and PCNSL is cure, and 
ongoing clinical research and international collaborative effort will be important for 
defining the role of – including specific protocols for – intraocular chemotherapy in 
achieving this aim. An internationally-based VRL registry that tracks results of 
diagnostic testing, plus the range of treatments and their outcomes, is presently under 
development, and should provide valuable real-world data that inform the use of 
intraocular chemotherapy for this rare cancer.     
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